Compare TORM plc (TRMD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs State Street SPDR S&P Biotech ETF — how do they compare? TORM plc trades at $29.14 (market cap $2.96B), while State Street SPDR S&P Biotech ETF trades at $159.7. The key difference: TORM plc pays a 9.66% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TORM plc nearer its low. Which is the better fit depends on your goals.
| TRMD | XBI | |
|---|---|---|
Market Cap | $2.96B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $34.87 | $164.28 |
52-Week Low | $19.07 | $88.79 |
Enterprise Value | $3.84B | — |
Dividend Yield | 9.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $28.97, down 0.75% today, with technical indicators showing bearish momentum despite oversold RSI conditions. The company maintains strong fundamentals with a P/E of 8.4, net margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, supported by strong tanker market conditions and a $0.70 dividend declaration.
The stock presents a compelling value opportunity with attractive valuation metrics and 100% analyst buy ratings. Key risks include earnings volatility from freight rate fluctuations and negative net cash flow trends. Upside catalysts include potential merger discussions with Hafnia and sustained strong tanker market fundamentals through 2026.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
